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Abstract 
Breast cancer is the second most fatal cancer in American women. To increase the life ex-
pectancy of patients with breast cancer new diagnostic and prognostic biomarkers and drug 
targets must be identified. A change in the glycosylation on a glycoprotein often causes a 
change in the function of that glycoprotein; such a phenomenon is correlated with cancerous 
transformation. Thus, glycoproteins in human breast cancer estrogen receptor positive (ER+) 
tissues and those in the more advanced stage of breast cancer, estrogen receptor negative 
(ER-)  tissues,  were  compared.  Glycoproteins  showing  differences  in  glycosylation  were 
examined by 2-dimensional gel electrophoresis with double staining (glyco- and total protein 
staining) and identified by reversed-phase nano-liquid chromatography coupled with a hybrid 
linear quadrupole ion trap/ Fourier transform ion cyclotron resonance mass spectrometer. 
Among the identified glycosylated proteins are alpha 1 acid glycoprotein, alpha-1-antitrypsin, 
calmodulin, and superoxide dismutase mitochondrial precursor that were further verified by 
Western blotting for both ER+ and ER- human breast tissues. Results show the presence of a 
possible glycosylation difference in alpha-1-antitrypsin, a potential tumor-derived biomarker 
for breast cancer progression, which was expressed highest in the ER- samples. 
Key words: Two-dimensional gel electrophoresis; Estrogen receptor positive and negative breast 
cancer; Biomarkers;  Alpha-1-antitrypsin;  Fourier  transform  ion  cyclotron resonance  mass spec-
trometry; Proteomics 
Introduction 
Breast cancer, if cancers of the skins are exclud-
ed, is the most frequently diagnosed cancer in Amer-
ican women and ranks immediately after lung cancer 
in mortality. According to the American Cancer Soci-
ety  Breast  Cancer  Facts  and  Figures,  approximately 
39,510 women (i.e., 14.4% of those diagnosed) will die 
from breast cancer in the USA. In 2012, estimated new 
breast cancer occurrences will reach 226,870, not in-
cluding in situ carcinoma. About 63,300 in situ breast 
carcinomas will be diagnosed in 2012  [1]. Based on 
proteomic and genomic studies, prognostic biomarker 
candidates  identified  from  breast  cancer  include 
growth factor receptors, steroid receptors, p53, Ki-67, 
cyclins, BRCA1 and BRCA2, urokinase plasminogen 
activator, p21, and pro- and anti-apoptotic factors [2]. 
The  Food  and  Drug  Administration  has  approved 
biomarkers CA 15.3, human epidermal growth factor 
receptor 2 (Her-2/neu), and CA27-29. However, the 
Ivyspring  
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combination of several biomarkers may produce the 
best prognosis [3].  
Breast cancer development and progression are 
regulated by estrogen and its receptor (ER) that is one 
of the predictive markers including progesterone re-
ceptor (PR), Her-2/neu, and ER for breast cancer. Yet, 
the anti-estrogen drug tamoxifen is often ineffective 
even  after  estrogen  receptor  positivity  [2].  Previous 
research has revealed that the tumorigenic epithelial 
cells  in  the  breast  duct  are  ER  positive  (ER+)  cells 
overlying  an  intact  myoepithelial  membrane,  but 
some  adjacent  cells  overlying  a  focally  disrupted 
myoepithelial  cell  layer  have  lost  their  response  to 
anti-estrogen  drugs  because  they  no  longer  express 
the ER. Moreover, the loss of the ER of those once 
tumorigenic  cells  at  the  invasion  site  contributes  to 
their higher potential for aggressiveness and invasion 
[4-6].  Therefore,  it  is  important  to  search  for  new 
prognostic and predictive markers for breast cancer 
progression from ER+ to ER-. 
Many  fundamental  cellular  processes  such  as 
cellular  differentiation,  control  of  cell  division, 
cell–cell recognition, adhesion, and malignant trans-
formation are controlled by oligosaccharides [7-10]. In 
most  cases,  oligosaccharides  are  conjugated  with 
other biomolecules known as glycol-conjugates. This 
process  is  observed  within  the  endoplasmic  reticu-
lum, Golgi apparatus, nucleus, and the cytoplasm of a 
cell. More than half of all proteins are glycosylated, 
either  N-  and/or  O-linked  [11].  Within  the  endo-
plasmic  reticulum  and  Golgi  apparatus,  O-linked 
glycans are usually attached to the peptide chain by a 
serine or threonine hydroxyl group. Mostly within the 
endoplasmic  reticulum,  N-linked  glycans,  the  pre-
dominant  carbohydrate  attachment  in  mammalian 
cells [12], are linked to the side chain by means of an 
amide  bond  to  asparagine  in  a  60-65%  conserved 
Asn-Xxx-Ser/Thr  motif  (in  which  Xxx  can  be  any 
amino acid except proline) [11, 13-14]. N-linked car-
bohydrates  are  frequently  found  together  with 
O-linked oligosaccharides in proteins such as fetuin 
[15], insulin receptor [16], IgG immunoglobulins [17], 
and  O-linked  glycoproteins  include  collagens  [18], 
mucins [19], and proteoglycans [20]. 
In breast cancer cells, changes in O-linked [21-26] 
and  N-linked  [27-28]  oligosaccharide  structures  are 
frequently correlated with cancerous transformation. 
For example, breast carcinomas may display altered 
expression of secreted and membrane-bound mucins, 
such  as  MUC1  and  MUC2  [29].  When  epithelial 
cell-surface mucin MUC1 is abnormally glycosylated, 
its  expression  shows  up-regulation  in  breast  cancer 
[30]. As a result, new epitopes are exposed leading to 
humoral  and  cell-mediated  immune  responses  [31]. 
Furthermore,  those  cancer-related  peptide  epitopes 
have been exploited as immunogens for cancer [32]. 
Therefore, identification of glycoproteins in the ER+ 
and ER- breast cancer tissues might reveal possible 
target(s) and identify putative biomarkers or tumor 
suppressors for pro- and pre-aggressive breast cancer 
stages.  Here,  we  compare  glycoproteins  in  breast 
cancer ER+ tissue and those in ER- tissue, the more 
aggressive  breast  cancer,  after  sample 
N-deglycosylation  to  compare  glycosylation  differ-
ences  with  controls  and  double  staining  of  the 
two-dimensional  electrophoresis  (2-DE)  gels.  Glyco-
proteins  were  identified  by  reversed-phase 
nano-liquid chromatography coupled with a hybrid 
linear  quadrupole  ion  trap/  Fourier  transform  ion 
cyclotron  resonance  mass  spectrometer 
(LC-LTQ/FT-ICR MS) and the glycosylation type for 
selected breast cancer-related proteins was verified by 
Western blotting. 
Materials and Methods 
Chemicals and materials  
Ready immobilized pH gradient (IPG) Strips, pH 
4-7, 11 cm long, were purchased from Bio-Rad. Dithi-
othreitol was purchased from Promega Corporation 
(Madison, WI). Bromophenol blue, Tris, SDS, Tricine, 
Ponseau S solution, bovine serum albumin (BSA), and 
cholamidopropyl  dimethylammonio  propanesul-
fonate  hydrate  (CHAPS)  were  purchased  from  Sig-
ma-Aldrich. Glacial acetic acid was purchased from 
EMD chemicals Inc. Urea was purchased from Fisher 
Scientific. Primary polyclonal anti-human rabbit an-
tibodies against ER-α MC-20 (MW 66 kDa), calmodu-
lin FL-149 (MW 17 kDa), and superoxide dismutase 
FL-222 (MW 25 kDa) were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). Polyclonal rab-
bit  anti-human  alpha-1-antitrypsin  A0012  (MW  ~57 
kDa)  was  purchased  from  DakoCytomation,  Den-
mark.  Rabbit  polyclonal  anti-human  alpha-1-acid 
glycoprotein ab440-2 (MW ~50 kDa) was bought from 
Abcam. Anti-rabbit IgG (whole molecule) peroxidase 
antibody  A0545  produced  in  goat  and  monoclonal 
mouse  anti-β-actin  antibody  A5316  (MW  42  kDa) 
were  purchased  from  Sigma-Aldrich.  Protease  and 
phosphatase inhibitor cocktails were purchased from 
Thermo-Pierce (Rockford, IL). 
Sample preparation 
Human ductal breast carcinoma tissue samples 
were obtained from the Cooperative Human Tissue 
Network-Midwestern Division. Tissues were cut into 
1 mm cubes on ice [33]. Tissues were suspended in 
cold tissue lysis buffer in 10 mM Tris pH 7.5, 130 mM 
NaCl, 1% octylglucopyranoside (OG), 1% CHAPS, 10  Journal of Cancer 2012, 3 
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mM sodium phosphate, 10 mM sodium fluoride, and 
1x  phosphatase  and  protease  inhibitor  (EDTA-free). 
Samples were centrifuged for 15 min at 14,000 rpm at 
4  ˚C  to  remove  insoluble  material.  The  supernatant 
layer was transferred to a new tube, and the pellet and 
the top lipid layer were discarded. Samples were then 
stored at -20 ˚C until further analysis. 
Determination of sample protein concentra-
tion 
Bicinchoninic  Acid  (BCA)  Protein  Assay  Kit 
(Pierce, Rockford, IL) was utilized to determine the 
protein concentration of all tissue lysates. Bovine se-
rum  albumin  was  used  to  make  the  standards  ac-
cording  to  the  manufacturer's  instructions.  The  en-
hanced  test  tube  protocol  was  followed  and  tissue 
lysis  buffer  was  the  diluent.  A  standard  curve  was 
employed to determine the protein concentration of 
the sample tissue lysates. 
Western blots 
Western blots were done essentially as described 
by Towbin et al. [34]. Samples were probed first by 
use of ER alpha primary antibody and all ER+ and 
ER- samples were identified (Figure 1). 25 μg of each 
sample  lysate  was  vacuum-dried.  Proteins  were  re-
constituted  with  sample  buffer  (1.25  mL  of  1  M 
Tris-HCl pH 6.8, 500 mg sodium dodecyl sulfate, 25 
mg  bromophenol  blue,  2.5  mL  glycol,  and  freshly 
added  1%  mercaptoethanol),  boiled  for  5  min,  and 
loaded onto a 10% polyacrylamide gel. The gel was 
electrophoresed at 50 V for 30 min, then at 100 V until 
the end of the separation. To transfer the separated 
proteins onto a nitrocellulose membrane, the gel was 
incubated in cold transfer buffer (100 mM CAPS, pH 
11) for 15 min, then electroblotted with 30 V at 4 ˚C 
overnight. Ponseau S solution was used to verify the 
transfer of the proteins onto the nitrocellulose and in 
some cases as a loading control. After 1 h of blocking 
with 5% BSA, the nitrocellulose was incubated in 1 
µg/mL of primary antibody ER-α anti-human rabbit 
followed by three 10 min Tris buffer saline with 1% 
Tween-20  (TBST)  washes  and  a  45  min  incubation 
with a horseradish peroxidase-conjugated secondary 
antibody  against  primary  antibody  (1:20,000  in  5% 
BSA). Chemiluminescence detection was achieved by 
applying  SuperSignal  West  Pico-Stable  Substrate 
(Pierce, Rockford, IL), Kodak Scientific Imaging Film 
(Kodak), and Fixer/Developer and Replenisher (Ko-
dak)  according  to  the  manufacturer’s  instructions. 
Similar procedures were followed to probe for alpha-1 
antitrypsin  (1:2,000),  alpha-1-acid  glycoprotein 
(1:1,000),  calmodulin  (1:200),  superoxide  dismutase 
(1:200),  and  β-actin  (loading  control)  (1:5,000)  pro-
teins, and antibodies were diluted in 1% BSA in TBST. 
For multiple probing on the same nitrocellulose, the 
membrane was treated with 30% H2O2 for 15 min at 37 
ºC while covered, then rinsed with TBST, followed by 
blocking  and  normal  probing  procedure  [35].  The 
H2O2 inactivates the peroxidase enzyme on the sec-
ondary antibody under the above conditions and en-
courages multiple probing with minimal loss of pro-
tein by comparison to stripping buffers [35]. 
Deglycosylation of sample 
The  GlycoProfileTM  II  Enzymatic  In-Solution 
N-Deglycosylation Kit (Sigma, Saint Louis, MO) was 
followed with ultra-pure water as the sample solvent. 
1 mg of tissue lysate from ER+ and ER- samples was 
boiled for 10 min until glycoproteins were identified 
and  then  for  30  min,  because  glycoproteins  like  al-
pha-1-antitrypsin  need  longer  incubation  for  dena-
turation prior to deglycosylation, according to man-
ufacturer’s  procedure.  Deglycosylated  samples 
(ER+D,  ER-D)  were  treated  with  50  μL  PNGase  F, 
whereas controls were treated with 50 μL ultra-pure 
water. The four tubes were incubated overnight at 37 
˚C.  The  deglycosylation  reaction  was  stopped  by 
heating at 100 ˚C for 10 min. After cooling to room 
temperature,  samples  in  the  four  tubes  underwent 
one  of  two  treatments:  they  were  either  vacu-
um-dried, reconstituted with 800 µL of lysis buffer (5 
M urea, 2 M thiourea, 4% CHAPS, 10% 2-propanol, 
5% glycerol, and 50 mM dithiothreitol (DTT)), divided 
into four aliquots of ~125 μg/200 μL of lysis buffer, 
and stored at -20 ˚C for further analysis; or they un-
derwent glycoprotein accumulation (see glycoprotein 
accumulation  section),  their  protein  concentration 
determined, and used for Western blot probing. 
Two dimensional gel electrophoresis  
For isoelectric focusing, the whole sample (125 
µg in 200 µL lysis buffer) of each resulting tube was 
loaded on 11 cm IPG strips at pH 4-7 (Bio-Rad). By use 
of PROTEAN IEF Cell (Bio-Rad), isoelectric focusing 
was performed according to the following procedure: 
rehydration of the IPG strips was done at 20 ˚C and 50 
V for 16 h followed by focusing the proteins at 250 V 
for 15 min and then at 8,000 V maintained for a total of 
50,000 V h per gel. 10% SDS-PAGE Tris-HCl Criterion 
(Bio-Rad, Hercules, CA) gels were prepared for 2-DE. 
The cathode buffer consisted of 0.1 M Tricine, 0.1 M 
Tris-HCl  pH  8.2,  and  0.1%  SDS  whereas  the  anode 
buffer consisted of 0.2 M Tris-HCl pH 8.9. Equilibra-
tion of the IPG-strips was conducted for 15 min in 2 
mL of equilibration buffer 1 (6 M urea, 2% SDS, 375 
mM  Tris-HCl  pH  8.8,  2%  DTT,  and  bromophenol 
blue) then for another 15 min in 2 mL of equilibration  Journal of Cancer 2012, 3 
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buffer 2 (identical to equilibration buffer 1 except with 
2%  iodoacetamide  instead  of  DTT).  The  IPG  strips 
were loaded onto the prepared gels, and run at 50 V 
for 30 min, and then at 130 V per gel until the end of 
the separation. Gels were fixed by overnight incuba-
tion in a 5:4:1 (methanol (MeOH): H2O: acetic acid) 
fixing solution. 
Double staining and scanning 
Some gels were double stained and scanned for 
visualization of the proteins. Multiplexed Proteomics 
Glycoprotein  Gel  Stain  Kit  (Molecular  Probes)  was 
used to stain 2-DE-fixed gels by Pro-Q Emerald 300 or 
488  (glycoprotein  stain)  followed  by  Sypro  Ruby 
(Bio-Rad,  Hercules,  CA)  total  protein  gel  staining. 
After glycoprotein staining, gels were scanned with 
300 nm UV illumination and for total protein staining, 
gels  were  scanned  with  a  Typhoon  9410  Scanning 
System (GE Healthcare, Amersham Biosciences) at an 
excitation wavelength of 457 nm detected at 610 nm. 
Spot counting 
Colony  counting  in  ImageQuant  TL  version  7 
was utilized to count gel spots with specific parame-
ters: rectangular area of interest, sensitivity 9,740, op-
erator size 11, noise factor 5, background 1, and au-
tomatic splitting 7. Images were filtered by means of a 
medium filter type. To get rid of gel speckling, filter 
options were set as maximum width and height of 5 
for .gel files or 10 for .tif files. The mean spot count 
was used for comparison in Figure 3. Error bars rep-
resent a 95% confidence interval, calculated from the 
standard deviation for each sample (see Supplemen-
tary Table 1). 
In-gel trypsin digestion 
After four iterations of 2-DE for each of the four 
samples,  glycoprotein  spots  were  manually  excised 
under UV light, combined in labeled microtubes, and 
analyzed by LC-LTQ 14.5 T FT-ICR MS. The gel pieces 
were de-stained with 25 mM ammonium bicarbonate 
in  50:50  (v/v)  acetonitrile  (ACN)/H2O  three  times 
and dried in a vacuum centrifuge. Gel spots were in-
cubated  with  15  µL  of  10  pmol/µL  trypsin  (Roche, 
Switzerland) solution at 37 °C overnight following a 
standard in-gel digestion protocol [36]. Then gel spots 
were  immersed  in  20  µL  of  75:25  (v/v)  ACN/H2O 
with 5% trifluoroacetic acid to extract peptides and 
vacuum dried. The digests were stored at -80 °C. 
Reversed phase capillary chromatography and 
mass spectrometry 
The tryptic peptides were dissolved in 10 µL 95:5 
(v/v)  MeOH/H2O  with  0.5%  formic  acid  and  were 
separated  and  purified  by  nano-HPLC,  pre-packed 
C18 column (New Objective, Ringoes, NJ, USA). An 
Eksigent  NanoLC  (Dublin,  CA)  delivered  a  45  min 
gradient (5 to 95% B) at 400 nL/min (solution A: 0.5% 
formic acid in 5% aqueous MeOH; solution B: 0.5% 
formic acid in 95% aqueous MeOH) [37]. 
Mass spectrometry was performed with a modi-
fied hybrid linear quadrupole ion trap (LTQ)/FT-ICR 
mass  spectrometer  (Thermo  Fisher  Corp.,  Bremen 
Germany) equipped with an actively shielded 14.5 T 
superconducting  magnet  (Magnex,  Oxford,  U.K.) 
[38-39]. The in-gel digested samples were analyzed by 
LC MS/MS with the 14.5 T LTQ FT-ICR MS operated 
in  top-5  data-dependent  mode:  high  resolution 
FT-ICR MS for precursor ions and low resolution LTQ 
MS/MS for product ions [40]. For each precursor ion 
measurement  (FT-ICR  MS),  mass  range  was  set  to 
m/z 400 – 1600, resolving power was set to 100,000 at 
m/z 400, and 3 million charges were accumulated in 
the LTQ prior to transfer to the ICR cell. The five most 
abundant ions were fragmented separately by colli-
sion-induced  dissociation  in  the  LTQ  for 
low-resolution  MS/MS  (3  microscans;  10,000  target 
ions; m/z = 2.0 isolation width; normalized collision 
energy, 35.0; activation Q, 0.250; 30 ms activation pe-
riod; and dynamic exclusion list size of 60 for 1 min). 
Automatic gain control produced less than 500 ppb 
rms  mass  error  with  external  calibration.  Data  was 
collected with Xcalibur software (Thermo) [41]. 
Data analysis and informatics 
Raw mass spectra were analyzed with a custom 
peak-picking algorithm. In addition to the 6 of rms 
baseline  noise  threshold,  an  additional  10%  sig-
nal-to-noise  threshold  was  applied  during 
peak-picking for MS/MS [42]. The resulting files were 
searched with MASCOT (Matrix Science, Cambridge, 
UK)  against  an  IPI  human  database  v3.30  (2  ppm 
mass tolerance for parent ions; 1.5 Da tolerance for 
MS/MS;  assumed  trypsin  protease  specificity;  one 
missed  cleavage).  Specified  variable  modifications 
include  oxidation  of  methionine,  iodoacetamide 
derivatization  of  cysteine,  and  phosphorylation  of 
serine, threonine, and tyrosine. 
Scaffold  (version  Scaffold  2.05,  Proteome  Soft-
ware Inc., Portland, OR) was used to validate MS/MS 
based  peptide  and  protein  identifications.  Peptide 
identifications were accepted if they could be estab-
lished at greater than 95.0% probability as specified 
by the Peptide Prophet algorithm [43]. Glycoprotein 
identifications were accepted if they could be estab-
lished at greater than 99.0% probability and contained 
at least two identified peptides. Protein probabilities 
were assigned by the Protein Prophet algorithm [44].  Journal of Cancer 2012, 3 
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Glycoprotein accumulation 
Glycoprotein Isolation Kit WGA (Thermo Scien-
tific) was used to accumulate the glycoproteins rich in 
N-acetylglucosamine  and  sialic  acid  from  the  ER+ 
PR+, ER+ PR-, and ER- PR- deglycosylated or glyco-
sylated samples. The ER and PR status of the breast 
cancer tissue samples was known from the pathology 
reports provided from the Cooperative Human Tissue 
Network-Midwestern  Division.  After  glycoprotein 
capture,  the  flow-through  was  also  collected  for 
Western blot probing. Sample protein concentration 
was  determined  as  mentioned  before  by  use  of  the 
BCA kit.  
Results and Discussion   
ER+ vs. ER-  
The expression of estrogen receptor alpha indi-
cates  the  aggressiveness  of  the  breast  cancer  stage, 
with the loss of this receptor correlated with a more 
aggressive stage of disease [5-6]. ER+ or ER- samples 
were verified with ER alpha antibody (Figure 1). Lane 
number  1  is  a  positive  control  according  to  its  pa-
thology report. Because the same amount of protein 
from similar ductal breast cancer tissue samples was 
loaded  in  the  lanes  (see  Figure  1,  Ponseau  S),  the 
lighter ER band indicates  the presence  of ER- cells. 
The  result  observed  in  lane  3  is  because  the  whole 
tissue lysate was used, not microdissections of only 
the ER- cells within the tissue [45]. 
The  double  stained  2-DE gels  of  ER+  and  ER- 
(Fig.  2A-2D)  were  spot-analyzed  with  ImageQuant. 
Averaged spot counts from 12 iterations of ER+ and 
ER- 2-DE gels were compared, of which 6 were double 
stained, while the others were stained only with Sy-
pro Ruby (for total protein). Results show that 30% of 
the total proteins are glycoproteins (Figure 3). To our 
knowledge there are no studies comparing the per-
centage of glycoproteins in ER+ and ER- breast cancer 
tissues.  
Identification of glycoproteins 
Double  stained  ER+  and  ER-  2-DE  gels  (Fig. 
2A-2D) were analyzed with Progenesis SameSpot v3.3 
software  (Nonlinear  Dynamics,  Newcas-
tle-upon-Tyne,  UK).  The  comparison  between  2-DE 
gels of controls to ER+D and ER-D shows significant 
differential  glycosylations  in  some  glycoproteins 
(with p <0.05 and power >0.8) present in both ER+ 
and  ER-  samples  (Fig.  2A-2D).  Spot  detection  and 
matching were performed automatically by the soft-
ware whereas warping was done manually. Statisti-
cally  significant  glycoprotein  spots  were  excised, 
combined  from  several  iterations,  and  analyzed  by 
high-resolution LC-LTQ/FT-ICR MS. Table 1 shows 
the  list  of  identified  glycoproteins.  Some  glycopro-
teins  were  identified  in  both  ER+  and  ER-  human 
breast tissue samples indicated in the MS/MS sample 
location in Table 1, including alpha-1-acid glycopro-
tein (A1A), alpha-1-antitrypsin glycoprotein (A1AT), 
annexin A1, peroxiredoxin-1, malate dehydrogenase 
mitochondrial  precursor,  myosin-reactive  immuno-
globulin kappa chain variable region, and superoxide 
dismutase  [Mn]  mitochondrial  precursor  (SOD2). 
Calmodulin (CaM) (Figure 2, spot 3) was identified in 
the ER- samples as indicated in Table 1, yet was also 
seen in ER+ samples, as later verified by Western blot. 
Immunoglobulins  identified  in  Table  1  are  proteins 
available in the cancer tissue sample but not specifi-
cally from ER+ or ER- breast cancer cells. Table 1 also 
lists  the  possible  N-glycosylation  sites  and  the 
O-glycosylation  sites  if  available  from 
www.cbs.dtu.dk/services/NetNGlyc/  and 
www.cbs.dtu.dk/services/NetOGlyc/ [46-47]. 
The  disappearance,  or  intensity  decrease,  of 
glycoprotein  spots  after  deglycosylation  treatment 
indicates that they are mainly N-glycosylated, such as 
A1A  and  A1AT  (Figure  2,  spots  1  and  2;  Figure  4, 
spots  1  and  2).  Spots  1  through  10  show  a  similar 
trend  of  expression,  in  the  total  protein  and  glyco-
protein stained gels, which are slightly higher in the 
ER+ than the ER- samples (Figure 4). This trend was 
also  seen,  yet  more  obvious,  in  our  previous  work 
with microdissected ER+ and ER- breast cell samples 
[45], because lysates of ER- microdissections include 
dramatically lower abundance ER+ cell proteins than 
ER-  whole  tissue  lysates.  The  major  problem  with 
microdissections however, is sample availability. 
 
 
 
Figure 1. Western Blot to verify the presence of estrogen re-
ceptor in breast tissue samples. Western blot of 25 µg of ductal 
breast cancer tissue samples (1, 2, & 3) for estrogen receptor alpha 
are shown on the right side of the figure. The left side represents 
those samples in Ponseau S staining that shows the total loading of 
protein. Sample 1 is known to be ER+ from its pathology report. 
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Figure 2. 2-DE gel scans presenting 
glycoproteins versus total proteins. 
Double staining 2-DE gels of human 
breast tissue samples with estrogen 
receptor  alpha  positive  (ER+),  es-
trogen receptor alpha negative (ER-) 
samples,  and  their  treated 
N-deglycosylated  samples  (ER+D) 
and (ER-D). Double staining of 2-DE 
gels  utilized  Pro-Q  Emerald  300 
glycoprotein  staining  C  and  D  fol-
lowed by Sypro Ruby total protein 
gel staining A and B. 125 µg of total 
lysate was loaded on 4-7 pH ranged 
10% SDS-PAGE gels. The sugar cane 
molecular weight ladder provided in 
the Multiplexed Proteomics Glyco-
protein Gel Stain Kit is presented at 
the left of each 2-DE gel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Glycoprotein and total protein spot count 
in ER+ versus ER- samples. The mean number of total 
protein and glycoprotein in ER+ and ER- 2-DE gels 
was obtained from ImageQuant TL. Spot count data 
were collected from 12 iterations of 2-DE gels for 
ER+ and ER- total proteins and from 6 iterations of 
ER+ and ER- glycoproteins. Six out of 12 iterations 
had double staining for glycoproteins and total pro-
teins. Error bars represent a 95% confidence interval 
calculated from the standard deviation of each sam-
ple.  Journal of Cancer 2012, 3 
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Figure 4. Progenesis SameSpot v3.3 software results for the expression level of spots 1 through 10 after Sypro Ruby (total protein) and 
ProQ Emerald 300 glycoprotein staining of the ER+, ER+D, ER-, and ER-D gels. ER represents the estrogen receptor. ER+D represent the 
N-deglycosylated estrogen receptor positive sample. Error bars represent a 95% confidence interval calculated by the Progenesis 
SameSpot v3.3 software from the normalized-to-background peak volume and peak height of each spot/protein from each 2-DE gel. 
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Table 1. LC-LTQ/FTICR-MS identified common glycoproteins in ER+ and ER- breast cancer tissue samples.  
Index 
no. 
MS/MS 
sample 
location 
Gene Symbol and Protein name  Accession 
number 
pI  Mw 
kDa 
Protein ID 
probability 
Nb. of 
unique 
peptides 
Possible N-(top) or 
O-Glycosylation Sites 
(bold) 
% Seq. 
Coverage 
1  1+ [1-]  ORM1 Alpha-1-acid glycopro-
tein 1 precursor 
IPI00022429  4.93  24  100.00% 
[99.80%] 
4 [2]  33NATL, 56NKSV, 
72NKTE, 93NTTY, 
103NGTI 
21.90% 
[9.95%] 
2  2+ [2-]  SERPINA1 Alpha-1-antitrypsin 
precursor 
IPI00553177  5.26  47  99.80% 
[100.00%] 
2 [15]  70NSTN, 107NLTE, 
271NATA 
416T 
6.70% 
[35.90%] 
3  [3-]  CALM3; CALM2;CALM1 Cal-
modulin 
IPI00075248  4.09  17  [100.00%]  [7]  25NGTI  [50.70%] 
4  4+ [4-] 
(4+D) 
<4-D> 
IGHM IGHM protein  IPI00472610  7.5  53  100.00% 
[99.90%] 
(100.00%) 
<99.70%> 
8 [2] (8) 
<2> 
46NNSD, 209NASS, 
272NISE, 279NATF, 
439NVSL 
4S, 7T, 379T 
17.20% 
[3.97%] 
(20.70%) 
<3.77%> 
5  (5+D)  IGHG1 IGHG1 protein  IPI00844246  8.13  51  (99.80%)  (2)  180NSTY 
2T, 3T, 7S, 22T, 106T, 
108T, 233T 
(18.70%) 
6  (6+D) 
<6-D>  
ANXA1 Annexin A1  IPI00218918  6.75  39  (100.00%) 
<99.80%> 
(4) <2>  none NXS/T 
41T 
(11.80%) 
<8.09%> 
6  [6-] (6+D)  MDH2 Malate dehydrogenase, 
mitochondrial precursor 
IPI00291006  8.92  36  [100.00%] 
(100.00%) 
[3] (3)  117NATI, 145NSTI 
147T 
[11.80%] 
(11.80%) 
7  7+ [7-] 
<7-D> 
Myosin-reactive immunoglobu-
lin kappa chain variable region 
(Fragment) 
IPI00384401  8.74  12  99.80% 
[99.80%] 
<99.80%> 
2 [2] <2>  none NXS/T 
5T, 7S, 10T, 20T, 69T 
24.80% 
(24.80%) 
<24.80%> 
8  8+ [8-] 
(8+D) 
<8-D> 
PRDX1 Peroxiredoxin-1  IPI00000874  8.27  19  100.00% 
[100.00%] 
(100.00%) 
<100.00%> 
7 [6] (9) 
<4> 
none NXS/T 
54T 
43.30% 
[37.40%] 
(48.50%) 
<25.10%> 
9  9+ [9-] 
(9+D) 
<9-D> 
SOD2 Superoxide dismutase 
[Mn], mitochondrial precursor 
IPI00022314  8.35  25  100.00% 
[100.00%] 
(100.00%) 
<100.00%> 
3 [4] (5) 
<3> 
63NVTE, 97NHSI, 
212NVTE 
14.40% 
[19.80%] 
(24.80%) 
<14.40%> 
10  10+ 
(10+D) 
ENDOD1 Endonuclease do-
main-containing 1 protein pre-
cursor 
IPI00001952  5.55  55  99.80% 
(99.8%) 
2 (2)  none NXS/T 
308T, 310S, 314T 
5.40% 
(4.80%) 
The index number (same as the spot labeling in Figure 2), location from which each MS/MS sample was identified, gene symbol and protein 
name, accession number, isoelectric point (pI), calculated molecular weight (Mw) in kDa, the number of unique peptides, possible N-(top) or 
O-(bottom) glycosylation sites, the percentage sequence coverage of peptides, and the Scaffold protein identification probability for each 
protein are shown. The possible glycosylation sites were gathered from two websites: www.cbs.dtu.dk/services/NetNGlyc/ and 
www.cbs.dtu.dk/services/NetOGlyc/. N-glycosylation sites are presented as amino acid location-in-protein number followed by the con-
sensus amino acid letter symbols with the N-linked amino acid letter symbol in bold font. O-linked sites are presented as serine (S) or thre-
onine (T) amino acid letter symbols in bold font with the number referring to the amino acid location in the protein.  
Footnote: Number represents ER+, [Number] represents ER-, (Number) represents ER+D, and <Number> represents ER-D values. The 
values are separated by this respective order if identified in the corresponding gel(s).  
 
 
Importance of N-glycoproteins in breast can-
cer  
Several  of  the  identified  glycoproteins  are  im-
portant  in  breast  cancer.  For  example,  A1A,  A1AT, 
CaM, annexin A1, peroxiredoxin-1, immunoglobulin 
gamma-1C region, and SOD2 have all been found to 
play  roles  that  affect  breast  cancer  [48-54].  Since 
O-glycosylated proteins have been studied more than 
N-glycosylated  proteins,  this  study  focused  on  the 
N-glycosylated proteins A1AT, A1A, SOD2, and CaM 
and their significance in breast cancer. A1A (oroso-
mucoid)  is  an  acute  phase  plasma  protein,  synthe-
sized in the liver, that has been associated with neo-
plasia,  rheumatoid  arthritis,  and  severe  burns  [55]. 
When A1A serum concentrations are elevated it may 
play an immunosuppressive role by inhibiting mito-
gen  induced  lymphoproliferation  as  well  as  lig-
and-induced capping on the surface of human mon-
onuclear cells [56]. A1A’s only established function is 
that it acts as a carrier of basic and neutrally charged 
lipophilic compounds, and in medicine, it is known as 
the primary carrier of basic drugs, steroids, and pro- Journal of Cancer 2012, 3 
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tease inhibitors [57-58]. The membrane form of A1A, 
that is approximately 52 kDa, was found present on 
normal  human  lymphocytes,  granulocytes,  and 
monocytes and would subsequently be cleaved and 
released  as  a  42  kDa  soluble  serum  form  [59].  Ap-
proximately  45%  of  A1A’s  molecular  weight  is  car-
bohydrate  content  [60]  that  are  N-linked  glycosyla-
tions according to Table 1, supporting why a decrease 
in  signal  was  seen  when  samples  were 
N-deglycosylated  (Figure  4,  spot  2).  Testing  of  the 
serum A1A was shown to reflect prognosis and mon-
itor  progress  in  patients  with  early,  recurrent,  and 
disseminated breast cancer [48]. Plasma A1A concen-
tration  was  found  to  be  2  fold  higher  in  metastatic 
breast cancer from liver and visceral sites than from 
healthy  samples  [61].  These  findings  encourage  re-
search  to  reveal  potential  glycosylation  differences 
present on A1A affecting its function in breast cancer. 
A1AT  is  an  acute  phase  protein,  synthesized 
mainly in the liver, but also in neutrophils and some 
cancer cells [62-64]. It primarily functions as a serine 
protease  and  leukocyte  elastase  inhibitor.  Plasma 
concentration  of  A1AT  rises  during  inflammation 
[65],  infection,  and  malignant  diseases  [64,  66-67], 
which correlates with tumor progression [68]. Native 
A1AT  exists  as  an  inhibitory  active  form.  The 
non-inhibitory  forms  are  produced  by  cleavage  or 
degradation due to the action of matrix metallopro-
teinases (MMP) -1, -3, -7, -8, -11, or -26 [69-74]. Both 
forms  were suggested to  play a role in  modulating 
tumor growth and invasiveness [49, 74], as discussed 
below for the Western blot results. 
CaM is a calcium binding protein responsible for 
stimulating  enzymes  such  as  phosphatases  and  ki-
nases.  In  human  breast  cancer  cell  lines,  CaM  was 
found to be a regulatory partner of estrogen receptor 
alpha [75] and a modulator of Akt activity [76]. The 
concentrations of soluble and particulate CaM in ER+ 
tumors are significantly higher than similar fractions 
in ER- tumors [50]. We observed a similar trend of 
CaM in ER+ versus ER- samples (Figure 4, spot 3). The 
further interest is glycosylation difference of CaM in 
these samples. 
SOD2 converts superoxide radicals to hydrogen 
peroxide and oxygen, protecting the cell against their 
potential  damage.  In  cancer,  SOD2  is  reduced  and 
with it its anti-oxidant role, contributing to a number 
of  cancer  cell  properties,  including  altering  key  en-
zyme  activities  by  oxidizing  sulfhydryl  groups, 
changing  the  oxidation-reduction  state  of  various 
metal  ions,  damaging  key  subcellular  structures, 
breaking the DNA chain, and potential chromosomal 
and  mitochondrial  damage  [77].  According  to  one 
study,  the  expression  of  SOD2  expression  in  breast 
cancer does not correlate with proliferation or apop-
tosis  [78].  The  expression  of  SOD2  is  higher  in 
non-neoplastic breast epithelial cells and in situ car-
cinomas than in invasive breast cancer cells, suggest-
ing that SOD2 may act as a tumor suppressor during 
the  development  of  an  invasive  breast  carcinoma 
phenotype  [78].  Meanwhile,  SOD2  upregulates 
maspin, a protease inhibitor blocking tumor cell mo-
tility and invasion, supports that the downregulation 
of SOD2 may increase motility of cells and result in an 
increased invasive potential in breast cancer [54]. Re-
cently,  gene  expression  of  SOD2  was  also  seen 
downregulated  in  breast  cancer  ER-  MDA-MB-231 
co-cultured cells with nodal fibroblasts, in which the 
viability  and  migration  of  MDA-MB-231  was  en-
hanced [79]. Figure 4 also shows a decrease in SOD2 
(spot 9) expression in the ER- samples relative to the 
ER+ samples. 
A1AT,  A1A,  SOD2,  and  CaM  proteins  were 
probed for by means of Western blot to verify their 
presence  in  a  normal  breast  and  different  stages  of 
cancer tissue samples (Figure 5). Cancer tissues that 
are ER- and PR- (progesterone receptor negative) are 
those cancers that are not affected by anti-hormonal 
drugs and were proven to be more aggressive than 
ER+ PR+ breast cancer [4-6, 80]. A1AT shows several 
bands per sample, in which some show differential 
expression  among  the  different  samples  of  breast 
cancer. A1A, SOD2, and CaM were expressed in all 
the wells with no significant difference in expression 
between the cancer stages (Figure 7), yet their expres-
sion in the normal was higher than the ER+ PR- cancer 
sample (Figure 5, wells 1 and 4, and Table 2). 
 
 
Table 2. A1AT, A1A, SOD2, and CaM protein’s relative 
intensity ratio of cancer to their corresponding breast 
normal tissues.  
Ratio of Cancer to its Corre-
sponding Normal Sample 
(fold) 
A1AT  A1A  SOD2  CaM 
ER+PR+/N  0.42-0.6  0.91  0.46-0.6  0.32-0.43 
ER+PR-/N  0.21-0.5  0.5-0.67 0.18-0.6  0.24-0.5 
ER-PR-/N  0.7  0.7  0.46  0.52 
The protein relative intensity was produced by Adobe Photoshop 
6.0 by comparing the absolute intensity to B-actin from all Western 
blot trials. The absolute intensity for each protein in each sample 
was calculated by multiplying the mean and pixels of the band. N 
represents the normal breast sample provided with the breast can-
cer tissue sample from the same donor. ER+PR+ represents estro-
gen receptor and progesterone receptor positive breast cancer tissue 
sample. 
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Figure  5. Western blot for A1AT, A1A, SOD2, and CaM in: 
normal (well 1), ER+ PR+ (well 2), ER+ PR weakly + (well 3), ER+ 
PR- (well 4) (whose corresponding normal is in well 1), and ER- 
PR- (well 5) breast tissue samples. B-actin was used as a loading 
control. 25 µg of each sample was loaded onto a 10% SDS-PAGE 
gel. Novex® Sharp Pre-stained Protein Standard (Invitrogen) was 
used as the molecular weight marker (Mr). 
 
A1AT, SOD2, and CaM were also probed for to 
verify  any  differential  expression  within  ER+  PR+, 
ER+ PR-, and ER- PR- breast cancer versus their cor-
responding  normal  breast  tissues  (Figure  6).  SOD2 
shows a significant decrease (p <0.01 and p <0.05) in 
ER+PR+ and ER+PR- cancer samples compared with 
their  normal  tissue,  and  CaM  shows  a  similar  de-
crease (p =0.004 and p =0.1) in the same comparison 
(Table 2), but none of them exhibited significant dif-
ference among the different cancer samples (Figures 6 
and 7). The t-test p-value is calculated for each nor-
malized value and represents a confidence measure 
on how reproducible is an expression level measure-
ment. The student t-test compared the first data set 
with the second data set, with one-tailed distribution 
and  paired  type  specifications.  SOD2’s  results  are 
supported  by  another  study  that  showed  SOD2  ex-
pression was higher in normal versus cancer samples 
[78]. A1AT shows several bands per sample, in which 
some  expressions  vary  among  the  different  breast 
cancer  samples  and  between  the  normal  and  their 
cancer samples (Figure 6). A decrease was observed in 
the A1AT between the normal of ER+ PR+ and ER+ 
PR- versus their cancer samples (Table 2, p <0.05), but 
no significant difference between the cancer samples 
(Figure 7). A1AT deficiency is previously associated 
with higher risk of malignant lymphoma and cancers 
of the liver, bladder, gallbladder, and lung [81]. In a 
recent  study,  A1AT  showed  higher  expression  in 
human breast tumor tissues relative to normal breast 
tissues from healthy donors [64]. But comparison in 
this work between cancer and normal breast tissues 
from the same donor showed a decrease in the A1AT 
expression level in the cancer samples (Table 2). 
 
 
 
Figure 6. Western blot for A1AT, SOD2, and CaM in: normal 
(well 1), ER+ PR+ breast cancer tissue (well 2) whose corre-
sponding normal is in well 1, normal (well 3), ER+ PR- breast 
cancer tissue (well 4) whose corresponding normal is in well 3, 
normal (well 5), and ER- PR- breast cancer tissue (well 6) whose 
corresponding normal is in well 5. B-actin was used as a loading 
control. 25 µg of each sample was loaded on a 10% SDS-PAGE gel. 
Same molecular weight marker used in Figure 5. 
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Figure 7. A1AT, A1A, SOD2, and CaM’s expression level in breast cancer tissues. There is no significant difference among the expression 
level of any of these proteins in any of the presented cancer samples. The relative protein intensity was produced by Adobe Photoshop 6.0 
by comparing their absolute intensity to B-actins from all Western blot trials. The absolute intensity for each protein in each sample was 
calculated by multiplying the mean and pixels of the band. Error bars represent a 95% confidence interval calculated from the standard 
deviation of each sample. ER+PR+ represents estrogen receptor and progesterone receptor positive breast cancer tissue sample. 
ER+PR~+ represents a breast cancer tissue sample with ER+ and PR weakly positive. 
 
Glycosylation difference in different stages of 
cancer  
To verify if any difference in bands is due to a 
variation in the glycosylation pattern, more Western 
blots were performed probing for A1AT, A1A, SOD2, 
and CaM (Figure 8). Glycoproteins in ER+ PR+, ER+ 
PR-, and ER- PR- breast cancer tissue samples were 
enriched with a WGA glycoprotein isolation kit (Fig-
ure  8,  wells  1,  2,  and  3).  WGA  lectins  target  on 
N-acetyl  glucosamine  and  sialic  acid.  To  verify  the 
type of glycosylation linkage, the ER- PR- breast tissue 
sample was divided into: (1) a treated with PNGase F 
to N-deglycosylate it; and (2) untreated sample used 
as an ER- PR- control. Those prepared samples also 
underwent glycoprotein enrichment and were loaded 
in wells 4 and 5. Western blots were performed after 
enrichment (Figure 8). The flow-through during the 
glycoprotein enrichment was loaded in wells 6 to 10. 
No  probed  proteins  were  observed  in  the  negative 
control  (well  11),  bovine  serum  albumin  (see  Fig. 
8A-8H). 
After enrichment, A1AT was observed in wells 
1-3 and 5 (Fig. 8A). The band at molecular weight of 
~57 kDa is full length A1AT, and 52 kDa is a degraded 
form. Along with results from Figures 2 and 4, this 
result further confirms glycosylation of A1AT. In well 
4, only a band at molecular weight ~47 kDa was ob-
served. The existence of the same band with high in-
tensity in the flow-through (well 9) suggests that the 
drop of molecular weight is due to the deglycosyla-
tion. Although a faint band was not expected to be 
seen  in  well  4,  presumably  due  to  the  presence  of 
possible  O-linked  glycosylation  (Table  1)  and 
non-specific binding. Moreover, because WGA targets 
only  limited  glycoforms,  insufficient  resins,  and  at 
less than 100% efficiency, the glycosylated A1AT at 
molecular weight of ~52 kDa or 57 kDa was seen in 
wells 6-8 and 10. The lower molecular weight bands 
present in wells 6-10 are the result of A1AT degrada-
tion  by  matrix  metalloproteinases  (MMPs)  [69-74]. 
Wells 1-3 show that there is a differential expression 
of the glycosylated bands. For instance, the ~52 kDa 
proteins have highest expression in well 2, less in well 
1, and disappeared in well 3. This band is a result of 
MMP-7 or -26 cleaving off the C-terminus of A1AT 
causing  the  inactivation  of  A1AT’s  ~52  kDa 
N-terminus  [71,  74].  MMP-26  is  associated  with  ER 
tumors targeting A1AT [71] and the results from this 
study reported the same trend as we observed, ER+ 
PR+ and ER+ PR- samples (wells 1 and 2, Fig. 8A) 
showed the cleaved A1AT ~52 kDa band but the ER-  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
280 
PR- (well 3, Fig. 8A) did not. The cleaved C-terminal 
fragment of A1AT is not a simple degradation prod-
uct of the full-length A1AT, but a functionally active 
fragment. In human pancreas adenocarcinoma cells, 
A1AT  C-terminus  fragments  may  serve  as  tu-
mor-derived immunosuppressors, through the mod-
ulation of natural killer cell-mediated control of tumor 
growth,  resulting  in  larger  tumors  and  increased 
tendency  toward  metastasis  [82].  A1AT  C-terminus 
fragment was found to induce MDA-MB- 468 breast 
cancer cell proliferation and invasiveness [49]. In Fig. 
8B, a band less than 10 kDa may be representative of 
the A1AT’s C-terminus and was seen highest in the 
ER- PR- sample, well 8, compared to wells 6 and 7. 
The higher molecular weight bands could be the 
result of a post-translational modification by adding 
sugar moieties to native A1AT to increase its molecu-
lar weight and ultimately affect its function. At higher 
exposure to the nitrocellulose (Fig. 8B), a band ~69 
kDa appears in the ER- PR- sample (well 3, Fig. 8B, 
with * on its right) and barely in the ER+ PR- sample 
(well 2, Fig. 8B), but not in the ER+ PR+ sample (well 
1, Fig. 8B). Because samples were boiled for 30 min in 
fresh sample buffer during the preparation it disrupts 
protein-protein interaction. Meanwhile, the molecular 
weight  of  the  band  is  much  less  than  the  dimer  of 
A1AT.  Therefore,  this  band  may  be  the  result  of  a 
glycosylation. The  glycosylation of A1AT may be a 
derived immunosuppressor or contributor to develop 
the primary cancer into a more aggressive/malignant 
stage such as ER- PR-. To understand the relationship 
between glycosylation of A1AT and cancer develop-
ment, a further study on the sugar part needs to be 
performed. Since more exposure to the nitrocellulose 
was needed to be able to see this band, it is presuma-
bly low in abundance, and higher loading is needed to 
accumulate  more  of  this  band  for  further  study.
 
 
Figure 8. Western blot to verify any difference in bands is due to a glycosylation difference. Western blots for A1AT, A1A, SOD2, and 
CaM were performed with 10% SDS-PAGE gel. With a glycoprotein isolation kit WGA, 25 µg of accumulated glycoproteins from the 
breast cancer tissue samples ER+ PR+ (well 1), ER+ PR- (well 2), ER- PR- (well 3), ER- PR- N-deglycosylated (well 4) (same ER- PR- sample 
but N-deglycosylated), and ER- PR- control (well 5) (same ER- PR- sample used treated with water instead of PNGase F enzyme) were 
loaded onto the Western blot. Their flow-through, containing the rest of the proteins in each sample other than the WGA lectin-attached 
glycoproteins, was loaded onto the same Western blot in wells 6 to 10. As a negative control, bovine serum albumin was loaded in well 
11. Presented is the same Western blot at low and high exposure time to the nitrocellulose membrane for A1AT (A) & (B), A1A (C) & (D), 
and SOD2 (E) & (F), respectively, whereas only high nitrocellulose exposure of CaM and B-actin are presented as (G) and (H). The same 
molecular weight marker (kDa) was used as in Figure 5. The * in (B) points to the ~69 kDa band on its left.  Journal of Cancer 2012, 3 
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A1A also  showed  that  it  is  N-glycosylated  be-
cause of the observation of lower molecular weight 
band after deglycosylation digestion (Fig. 8C and D, 
wells 4 and 9). Along with 5 possible N-linked glyco-
sylation  sites  shown  in  Table  1,  it  further  confirms 
previous conclusions from Figures 2 and 4. But A1A 
has no glycosylation difference even with higher ex-
posure to the nitrocellulose (Fig. 8D). SOD2 shows no 
glycosylations, because no band was detected in wells 
1-3  and  5,  and  no  effect  was  noticed  due  to 
N-deglycosylation in well 9 (Fig. 8E and F). 
CaM is glycosylated as a 17 kDa band, though 
faint, was seen in the glycoprotein accumulated wells 
1-5, yet it proves that it is not N-glycosylated, because 
N-deglycosylation treatment in wells 4 and 9 did not 
affect the molecular weight of CaM (Fig. 8G). CaM 
may  be  glycated  or  O-glycosylated.  The  primary 
binding  specificity  sites  of  WGA  are  terminal 
(β-1,4)-linked N-acetyl glucosamine (GlcNAc) dimers, 
galactosyl (β -1,4) GlcNAc (β -1,3) repeats of large oli-
giosaccharides and also binds weaker to (α-2,3)- and 
(α-2,6)-linked  terminal  sialic  acid  residues  [83-85]. 
Because the glycosylated band is not a result of Glc-
NAc  or  sialic  acid  from  an  N-linked  sugar  to  CaM 
then for CaM to bind to the WGA resin it probably has 
an  O-GlcNAc,  yet  www.cbs.dtu.dk/services/ 
NetOGlyc/  website  did  not  show  possible 
O-glycosylation sites on CaM. Glycation involves the 
simple sugars glucose, fructose, and galactose; fruc-
tose and galactose have approximately ten times the 
glycation activity of glucose, the primary body fuel 
[86]. CaM may be glycated by glucose sugars at seven 
lysine residues on CaM, in which the carbonyl group 
of the sugar reacts with the amino group of the amino 
acid  producing  N-substituted  glycosylamine  and 
water (Maillard reaction) [87]. Further non-enzymatic 
reactions may change the N-glycosylamine to an ad-
vanced glycation end product. Glycation affects the 
function of CaM [88], for example, glycated-CaM ap-
pears to be less prone for binding calcium [89] and, 
therefore, CaM may be less capable to activate its en-
zyme targets. The N-substituted glucosamine at the 
lysine  residues  of  glycated-CaM,  after  further  reac-
tions, may resemble N-acetyl glucosamine and there-
fore may attach to WGA resin. The highest expression 
level  of  the  17  kDa  band  was  seen  in  the  ER-  PR- 
sample in wells 3 and 8 (Fig. 8G) when compared to 
the ER+ PR+ and ER+ PR- samples. 
B-actin, the loading control, (Fig. 8H) is not gly-
cosylated, as seen from the absence of bands in the 
glycoprotein enriched samples in wells 1-5. It showed 
up in the flow-through wells 6-8 but not in wells 9 and 
10. For reasons not known, the boiling and solutions 
used in the N-deglycosylation treatment  must have 
affected the B-actin protein. 
Conclusion 
 This study utilized N-deglycosylation and dou-
ble  staining  of  2-DE  gels  followed  by 
LC-LTQ/FTICR-MS identification and further verifi-
cation by Western blotting. A list of glycoproteins was 
identified  and  only  the  N-linked  were  verified  in 
normal,  ER+  PR+,  ER+  PR-,  and  ER-  PR-  human 
breast cancer tissues. Several of those identified pro-
teins play a role in breast cancer; yet only those that 
show  a  glycosylation  difference,  that  may  have  af-
fected  their  function  and  thus  played  a  role  in  the 
progression  of  breast  cancer,  were  of  interest.  The 
native  form  of  A1AT  controls  excessive  proteolytic 
activity of enzymes released by leukocytes at the site 
of  inflammation.  An  imbalance  between  neutrophil 
elastase and A1AT is thought to cause tissue damage 
creating a tissue favorable for malignant progression 
[82]. The native form of A1AT thus acts like a tumor 
suppressor. For instance, A1AT blocks transforming 
growth factor (TGF) alpha that is known to stimulate 
proliferation [90], upregulates levels of TGF-β1[49] (a 
negative growth regulator of breast tumor cells) [91], 
decreases release level of interleukin 6 (an autocrine 
and  paracrine  growth  factor  for  various  cancers  in-
cluding breast cancer), and inhibits cell proliferation 
[49].  Matrix  metalloproteinases  (MMPs)  regulate 
A1AT’s activity and can cleave off the C-terminus into 
shorter  active  fragments.  Studies  have  shown  that 
A1AT  C-terminus  fragments  were  tumor-derived 
immunosuppressors  that  promote  cancer  metastasis 
[49, 74, 82]. A1AT was shown to be expressed higher 
in  human  breast  tumor  tissues  when  compared  to 
normal  breast  tissues  from  healthy  donors  [64];  yet 
results from this study compared cancer and normal 
breast  tissues  from  the  same  donor  and  show  an 
overall decrease in the native A1AT expression level 
of the cancer samples relative to their corresponding 
normal  tissue  samples.  This  phenomenon  could  be 
due to both the degradation of native A1AT as pre-
viously proposed, and a post-translational modifica-
tion  adding  carbohydrate  moieties  to  the  native 
A1AT,  thereby  increasing  its  molecular  weight, 
whereas  Figure  8  shows  that  both  scenarios  exist 
simultaneously. In breast cancer cells, a difference in 
an  N-linked  [27-28]  oligosaccharide  structure  was 
frequently correlated with cancerous transformation. 
Another  study  reflected  that  A1AT  expression  was 
highest in the more aggressive cell line of a series of 
isogenic breast cancer cell lines [92]. Again these re-
sults and findings suggest that A1AT, in all its forms, 
plays an important role in carcinogenesis. A1AT with 
a glycosylation difference, that affects the function of  Journal of Cancer 2012, 3 
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A1AT  and  is  recognized  by  an  increase  in  native 
A1AT’s  molecular  weight,  was  seen  highest  in  the 
more aggressive ER- PR- human breast cancer sample 
relative to the ER+ PR+ and ER+ PR- human breast 
cancer  samples.  A1AT  glycosylation  sites,  possible 
sugars, and antennary structures at each site are al-
ready determined in human cerebrospinal fluid [93] 
and human plasma [94], which should make it feasi-
ble to compare A1AT in ER+ and ER- breast cancer 
and identify the A1AT’s differential sugars in the ER- 
samples. Further study is needed to verify if this tu-
mor derived glycosylation difference is affecting the 
function  of  A1AT  in  the  aggressive  stage  of  breast 
cancer. 
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